전체 논문 (226편 · 1/8)
-
Adding pembrolizumab to a platinum doublet may be a new option for advanced penile cancer.
-
Tarlatamab plus anti-PD-L1 as first-line maintenance for ES-SCLC demonstrates promising results.
-
Dynamic signature for the effectiveness of anti-PD-1 therapy combined with vascular normalization therapy in recurrent glioblastoma: A randomized phase 2 trial.
-
Retrospective analysis of cutaneous immune-related adverse events following checkpoint inhibitor therapy in melanoma patients reveals increased risk associated with the HLA-B*51:01 allele.
-
Nine-year data show sustained benefit of nivolumab in patients with high-risk resected melanoma.
-
A phase 1b/2 study of cabozantinib in combination with pembrolizumab in advanced cutaneous melanoma.
-
Correction to "Retrospective analysis of cutaneous immune-related adverse events following checkpoint inhibitor therapy in melanoma patients reveals increased risk associated with the HLA-B*51:01 allele".
-
Baseline tumor burden and outcomes in patients with rare cancers treated with immunotherapy (Southwest Oncology Group trial S1609).
-
Objective response rate predicts survival in recurrent or metastatic head and neck squamous cell carcinoma treated with immune checkpoint blockade but not with targeted therapy: A retrospective multicenter study.
-
FDA approves perioperative pembrolizumab plus enfortumab vedotin for cisplatin-ineligible MIBC.
-
Correction to "Chronic myelomonocytic leukemia in the young (aged 50 years and younger): Divergent clinical and molecular characteristics from the elderly".
-
Exploring an independent association between rituximab-cyclophosphamide-doxorubicin-vincristine-prednisolone dose intensity and clinical outcomes in large B-cell lymphoma: Analyses of subsequent endpoints following a complete response in a real-world cohort of 1369 patients.
-
A first-line regimen combining Bruton's tyrosine kinase and programmed cell death protein-1 inhibitors with chemotherapy excluding methotrexate achieves high response rates in primary central nervous system lymphoma.
-
Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real-life Italian multicenter study.
-
Glucose-6-phosphate dehydrogenase deficiency is associated with improved survival in patients with acute myeloid leukemia treated with venetoclax and azacitidine.
-
Correction to "Risk scores predicting disease progression in early-stage chronic lymphocytic leukemia: comparative analysis and usefulness of IGHV subset #2 to improve their accuracy".
-
Exploratory association of muscle and adipose tissue indices with clinical outcomes in aggressive lymphomas.
-
Clinical, genetic, and familial features of POT1 tumor predisposition syndrome.
-
Correction to "Clinical and immunologic characteristics of nonhematologic autoimmune disorders in chronic lymphocytic leukemia".
-
Secondary primary malignancies in indolent non-Hodgkin lymphoma patients receiving frontline bendamustine-rituximab.
-
Two new options for NPM1-mutated relapsed, refractory acute myeloid leukemia: Researchers are looking into whether revumenib or ziftomenib can be combined with first-line standard-of-care treatment options.
-
Correction to "Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia".
-
Combination of mitoxantrone hydrochloride liposome with cyclophosphamide, vincristine, and prednisone for patients with treatment-naive peripheral T-cell lymphoma: A multicenter, open-label, single-arm, phase 1b trial.
-
Combined prognostic impact of complex karyotype and KIT mutations refines risk stratification in t(8;21) acute myeloid leukemia.
-
Preclinical circulating tumor DNA shedding duration and prognostic implications of modeling 3669 patients with cancer in the American Cancer Society Cancer Prevention Study-3 and Circulating Cell-Free Genome Atlas Substudy 3.
-
Outcome of second-line therapy in adult B-cell acute lymphoblastic leukemia.
-
Treatment and outcomes of pulmonary mucosa-associated lymphoid tissue lymphoma: A multicenter analysis of 186 patients.
-
Reassessing adverse prognosis of acute myeloid leukemia harboring BCR::ABL1 in the era of tyrosine kinase inhibitors: A real-world analysis from the PETHEMA registry.
-
Factors influencing front line treatment of chronic lymphocytic leukemia: A French real-world study.
-
Assessing patient perspectives on enrollment in lymphoma clinical trials.